Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03723967
Title FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel (FRAIL-IMMUNE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Centre Leon Berard

hypopharynx cancer

head and neck squamous cell carcinoma

oral squamous cell carcinoma

laryngeal squamous cell carcinoma

oropharynx cancer


Carboplatin + Durvalumab + Paclitaxel

Age Groups: senior | adult
Covered Countries FRA

No variant requirements are available.